The Design and Results of TRINOVA-1

January 29, 2014
Bradley J. Monk, MD

Bradley J. Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the TRINOVA-1 trial.

Clinical Pearls

Bradley J. Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the TRINOVA-1 trial.

  • The TRINOVA-1 trial studied trebananib plus paclitaxel versus placebo plus paclitaxel in 919 patients who had recurrent ovarian cancer and up to three prior lines of therapy
  • Trebananib plus weekly paclitaxel improved the hazard ratio for progression by 0.66
  • The combination also improved response rate and the survival data, although not yet mature, showed a hazard ratio of 0.86